Negative impactCompany
FSSAI issues notice to Dr. Reddy’s, Nestle Health Science, e-comm players over misleading claims
BusinessLine 1 hr ago·8 Oct 2026, 4:16 pm
The Food Safety and Standards Authority of India (FSSAI) has issued a formal notice to Dr. Reddy’s Laboratories and Nestle Health Science, along with major e-commerce platforms, regarding the marketing of the diabetes management product 'Celevida GLP+'. The regulator flagged these entities for allegedly making misleading claims about the product's efficacy on digital marketplaces.
This development is significant for investors as it signals increased regulatory scrutiny on the health and wellness sector. For Dr. Reddy’s and Nestle, this could lead to reputational damage and potential financial penalties if they fail to rectify the non-compliant advertisements immediately.
Investors should monitor the companies' official responses and any subsequent actions by FSSAI. The outcome will likely influence the stock performance of the involved entities and set a precedent for how health supplements are advertised online in India.
Excerpt from BusinessLine
The Food Safety and Standards Authority of India (FSSAI) on Thursday said it has issued notices to Dr. Reddy’s and Nestle Health Science Ltd besides Flipkart India, Amazon India, Netmeds Healthcare and Tirupati Wellness Pvt Ltd over alleged non-compliant claims and ads regarding a nutritional supplement. The regulator…Read the original at BusinessLine
Key takeaways
- Category: Company.
- AI reads the tone as negative (potentially bearish) for the stock.
- Assessed as a significant, market-relevant update.
Why it matters
A meaningful update worth tracking. The tone is negative — watch for downside reaction. Use the price and stock snapshot to gauge how the market is responding.
